Ranbaxy ties up with UK firm to market its cancer pill
Facebook Twitter google+ RSS Feed

Ranbaxy ties up with UK firm to market its cancer pill

By SiliconIndia   |   Tuesday, 29 October 2002, 08:00 Hrs
Printer Print Email Email
Ranbaxy Laboratories, a pharmaceutical company, on Monday signed an agreement with UK-based K S Biomedix for marketing TransMID, a new biological drug for treatment of high grade glicoma, a terminal brain cancer.



NEW DELHI: Brian Tempest, Ranbaxy pharmaceutical president, said, "We will continue to provide novel products for Indian customers and believe that TransMID will help us strengthen our position in the high value oncology segment,"

Dr Steven Powell, CEO of K S Biomedix, said, "This latest agreement is the fourth territory licensed for TransMID this year, extending the commercial coverage for the product significantly."


Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Philips
Sr. Executive
ISB
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
NIC
Reena Khanna
Founder
Solitaireworld
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset
SPOTLIGHT